EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM

Fu-Li Qin, Guo-You Sang, Xiao-Qin Zou iD, Dao-Hai Cheng iD

Canadian Journal of Gastroenterology and Hepatology · 24.03.2022 · 2022 · 1-9

DOI: 10.1155/2022/5914593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, erschienen am 24.03.2022. Verfasst von Fu-Li Qin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The presence of serious toxicities is a major problem in the treatment of childhood acute lymphoblastic leukemia (ALL). The objective of this research is to evaluate drug-induced liver injury (DILI) during consolidation therapy in childhood ALL.

Methods

Clinical data of pediatric patients who received consolidation therapy between August 2012 and July 2018 were collected. Characteristics (incidences and patterns) of DILI at different stratifications were determined. Risks of DILI were evaluated using binary logistic regression analysis. Drug causality assessment was carried out by the updated Roussel Uclaf Causality Assessment Method (RUCAM).

Results

Patients with high risk (HR) and standard risk (SR)/intermediate risk (IR) received 270 and 1539 courses of consolidation therapy, respectively; among these courses, 15 (5.6%) and 38 (2.5%) developed DILI. The occurrences of DILI in SR/IR patients were primarily associated with age (≤5.2 years), treatment course (≥5), and baseline serum parameters before treatment (cystatin C > 0.79 mg/L, albumin ≤45 g/L, and gamma-glutamyl transpeptidase (GGT) > 17 U/L). The ROC curve generated using the parameters assigned to specific values achieved an area under the curve (AUC) of 0.846 (95% CI 0.827–0.863) with a cutoff value of 3, and the sensitivity and specificity were 94.7% and 62.3%, respectively. For HR patients, a decrease in baseline albumin and elevation of baseline liver enzymes (GGT and aspartate aminotransferase) were observed in DILI cases compared with the non-DILI subjects. In the SR/IR group with DILI, the causality gradings for high-dose methotrexate (HD-MTX) were highly probable in 5 (13.2%) cases, probable in 31 (81.6%) cases, and possible in 2 (5.3%) cases. Among the DILI cases in HR-1, HR-2, and HR-3 groups, high causality gradings (probable + highly probable) were detected in “100% of HD-MTX + 57% of high-dose cytarabine (HD-Ara-C),” “100% of HD-MTX + 20% of pegylated asparaginase (PEG-ASP),” and “100% of HD-Ara-C + 33.3% of PEG-ASP,” respectively.

Conclusion

Incidence of DILI in HR patients was significantly higher than that in SR/IR patients. A number of potential risk factors were identified, among which the preexisting liver conditions were suggested as shared risk factors in all stratification groups. HD-MTX, HD-Ara-C, and PEG-ASP were the main causative agents of DILI. The knowledge generated from this study will be helpful for understanding characteristics of DILI during consolidation treatment in childhood ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryPrecursor Cell Lymphoblastic Leukemia-LymphomaAspartate AminotransferasesChildChild, PreschoolConsolidation ChemotherapyHumans

Substanzen

Aspartate Aminotransferases

Autor:innen und Institutionen

  • Department of Pharmacy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Pharmacy, Guangxi Zhuang Autonomous Region Workers' Hospital, Nanning, China.
  • Department of Medical Research, First Affiliated Hospital of Guangxi Medical University, Nanning, China.

ORCID-Profile: Xiao-Qin Zou, Dao-Hai Cheng

Förderung

  • Guangxi Health Commission

Zitieren

APA

Qin, F. L., Sang, G. Y., Zou, X. Q., & Cheng, D. H. (2022). Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM. Canadian Journal of Gastroenterology and Hepatology, 2022, 1-9. https://doi.org/10.1155/2022/5914593

Vancouver

Qin FL, Sang GY, Zou XQ, Cheng DH. Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM. Canadian Journal of Gastroenterology and Hepatology. 2022;2022:1-9. doi:10.1155/2022/5914593

BibTeX
@article{Qin2022,
  author = {Qin, Fu-Li and Sang, Guo-You and Zou, Xiao-Qin and Cheng, Dao-Hai},
  title = {Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM},
  journal = {Canadian Journal of Gastroenterology and Hepatology},
  year = {2022},
  volume = {2022},
  pages = {1--9},
  doi = {10.1155/2022/5914593}
}
Kostenlos starten →